HOST-EXAM Bleeding vs Ischemic Risk Index

Clinical calculation support · Verify results before clinical use

Patient and procedural variables

Calculate the DAPT score and review selected bleeding-risk signals.

Clinical decision support
Patient data
Displayed as a signal only; not used to calculate an exact PRECISE-DAPT score.
Bleeding history
Prior spontaneous bleeding requiring medical attention?
DAPT score criteria

The DAPT score was developed for selected patients who completed 12 months of DAPT after PCI without major ischemic or bleeding events.

Current cigarette smoker?
Diabetes mellitus?
MI at index presentation?
Prior PCI or prior MI?
Paclitaxel-eluting stent?
Stent diameter <3 mm?
CHF or LVEF <30%?
Saphenous vein graft PCI?
Reset form

How to interpret this tool

The DAPT score estimates the balance of ischemic benefit and bleeding harm from continuing dual antiplatelet therapy beyond one year after coronary stenting in a selected population. It is not a general ACS score and should not be applied indiscriminately at the time of PCI.

DAPT score point assignments

VariablePoints
Age ≥75 years−2
Age 65 to <75 years−1
Age <65 years0
Current cigarette smoking+1
Diabetes mellitus+1
MI at presentation+1
Prior PCI or prior MI+1
Stent diameter <3 mm+1
Paclitaxel-eluting stent+1
CHF or LVEF <30%+2
Saphenous vein graft PCI+2

Bleeding-risk signals and limitations

PRECISE-DAPT uses age, creatinine clearance, hemoglobin, WBC count, and prior spontaneous bleeding. This tool displays selected signals for review but does not calculate PRECISE-DAPT or classify a validated score ≥25.

  • CrCl is estimated using Cockcroft–Gault and depends on entered weight and creatinine.
  • Displayed thresholds are screening prompts, not a validated substitute for PRECISE-DAPT or ARC-HBR assessment.
  • A DAPT score ≥2 does not override important bleeding risks or replace shared clinical decision-making.

References

Yeh RW, Secemsky EA, Kereiakes DJ, et al.Development and Validation of a Prediction Rule for Benefit and Harm of Dual Antiplatelet Therapy Beyond 1 Year After Percutaneous Coronary Intervention. JAMA. 2016;315(16):1735–1749. doi:10.1001/jama.2016.3775
Costa F, van Klaveren D, James S, et al.Derivation and validation of the PRECISE-DAPT score. Lancet. 2017;389(10073):1025–1034. doi:10.1016/S0140-6736(17)30397-5; PMID 28290994.
ACC/AHA.2016 Focused Update on Duration of Dual Antiplatelet Therapy in Patients With Coronary Artery Disease. JACC guideline publication.
Clinical disclaimer: This educational decision-support tool does not replace validated risk models, guideline review, or clinician judgment. Confirm the intended population and timing before applying the DAPT score. Do not change antiplatelet therapy solely on the basis of this result.